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Objective. Although oral bisphosphonates are ef-
fective treatments for postmenopausalwomenwith osteo-
porosis, oral dosing may be unsuitable for some pa-
tients. An efficacious intravenously administered
bisphosphonate could be beneficial for such patients.
Ibandronate, a potent nitrogen-containing bisphospho-
nate, can be administered using extended dosing inter-
vals, either orally or by rapid intravenous injection. The
aim of this study was to identify the optimal intravenous
dosing regimen for ibandronate in postmenopausal
women with osteoporosis.
Methods. In a randomized, double-blind, double-
dummy, phase III, noninferiority study, we compared 2
regimens of intermittent intravenous injections of iban-
dronate (2 mg every 2 months and 3 mg every 3 months)
with a regimen of 2.5 mg of oral ibandronate daily, the
latter of which has proven antifracture efficacy. The
study group comprised 1,395 women (ages 55–80 years)
who were at least 5 years postmenopausal. All patients
had osteoporosis (lumbar spine [L2L4] bone mineral
density [BMD] T score less than 2.5). Participants
also received daily calcium (500 mg) and vitamin D (400
IU). The primary end point was change from baseline in
lumbar spine BMD at 1 year. Changes in hip BMD and
in the level of serum C-telopeptide of type I collagen
(CTX) were also measured, as were safety and tolera-
bility.
Results. At 1 year, mean lumbar spine BMD
increases were as follows: 5.1% among 353 patients
receiving 2 mg of ibandronate every 2 months, 4.8%
among 365 patients receiving 3 mg of ibandronate every
3 months, and 3.8% among 377 patients receiving 2.5 mg
of oral ibandronate daily. Both of the intravenous
regimens not only were noninferior, but also were
superior (P < 0.001) to the oral regimen. Hip BMD
increases (at all sites) were also greater in the groups
receiving medication intravenously than in the group
receiving ibandronate orally. Robust decreases in the
serum CTX level were observed in all arms of the study.
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Both of the intravenous regimens were well tolerated
and did not compromise renal function.
Conclusion. As assessed by BMD, intravenous
injections of ibandronate (2 mg every 2 months or 3 mg
every 3 months) are at least as effective as the regimen
of 2.5 mg orally daily, which has proven antifracture
efficacy, and are well tolerated.
Oral bisphosphonates are the current mainstay of
treatment for postmenopausal osteoporosis. Results of
several large clinical trials attest to the efficacy of oral
bisphosphonates in reducing fracture risk (1–6) as well
as their favorable safety and tolerability profile (1–9).
However, oral administration may be unsuitable in some
populations, such as patients with gastrointestinal (GI)
intolerance or those with difficulty complying with the
requisite procedures for oral dosing (e.g., patients with
cognitive impairment or those receiving several other
oral medications). Oral dosing is also contraindicated in
some patients (e.g., those with abnormalities of the
esophagus that delay esophageal emptying). The addi-
tional availability of an intravenous (IV) bisphosphonate
preparation could therefore be clinically advantageous
for use in such patients.
Ibandronate is a nitrogen-containing bisphospho-
nate, the potency of which (10), combined with its
favorable tolerability (1) and bone-binding characteris-
tics (11), allow it to be administered orally, using ex-
tended dosing intervals. In a study of 2,946 postmeno-
pausal women with osteoporosis, oral ibandronate given
daily or intermittently (between-dose interval of 2
months) produced substantial antifracture efficacy; the
reductions in vertebral fracture risk at 3 years were 52%
(daily dosing) and 50% (intermittent dosing), and both
regimens were well tolerated, with a safety profile
similar to that of placebo (1,2). At 1 year, relative risk
reductions of 58% and 59% were observed for new
morphometric and combined new moderate and severe
vertebral fractures, respectively (1,12). When given as a
once-monthly regimen, oral ibandronate was at least as
effective (as measured by increases in bone mineral
density [BMD]) as the daily regimen, with similar toler-
ability (13).
Because ibandronate is a highly potent inhibitor
of bone resorption (10), it can also be administered as a
rapid IV injection over 15–30 seconds, with extended
dose-free intervals. When given once every 3 months, IV
ibandronate produced dose-dependent and clinically
meaningful increases in BMD and decreases in the levels
of biochemical markers of bone turnover in postmeno-
pausal women with osteoporosis (14,15). The same
regimen also significantly reduced vertebral fracture risk
in patients with corticosteroid-induced osteoporosis
(16). In those 3 studies, IV ibandronate was well toler-
ated, with a safety profile similar to that of placebo, and,
notably, no indications of renal toxicity were observed.
To identify the optimal IV dosing regimen for
ibandronate in postmenopausal women with osteo-
porosis, the Dosing IntraVenous Administration
(DIVA) study was initiated to compare the efficacy and
safety of IV ibandronate administered every 2 months or
every 3 months with the efficacy and safety of the
approved regimen of 2.5 mg of ibandronate adminis-
tered orally. The principal hypothesis for the DIVA
study was that the efficacy of the 2 IV regimens would be
noninferior to the daily oral regimen after 12 months of
treatment. The study is continuing (in a blinded manner)
for an additional 12 months, at which point a confirma-
tory analysis will be performed.
PATIENTS AND METHODS
Role of the funding source. This research was sup-
ported by F. Hoffmann-La Roche Ltd and GlaxoSmithKline.
F. Hoffmann-La Roche and GlaxoSmithKline had a role in
study design, and in data analysis and interpretation but not in
data collection. All authors contributed to the manuscript and
approved the content prior to submission. F. Hoffmann-La
Roche Ltd supplied the study drug.
Study participants. Women ages 55–80 years who were
at least 5 years postmenopausal and who had osteoporosis
(mean lumbar spine [L2–L4] BMD T score less than 2.5 but
greater than or equal to 5.0) were screened for eligibility.
Women who had previously received IV bisphosphonates at
any time or who, in the previous 6 months, had received oral
bisphosphonates or any other drug affecting bone metabolism
were excluded, as were those who had renal impairment
(serum creatinine level 2.4 mg/dl), a history of major upper
GI disease, or allergy to bisphosphonates.
Study design and treatments. DIVA is a 2-year, ran-
domized, double-blind, double-dummy, phase III, noninferior-
ity study involving 58 centers in the US, Canada, Mexico,
Europe, Australia, and South Africa. The study protocol was
approved by local ethics committees at all centers, and all
patients gave written informed consent. The study conformed
in full with the principles of the Declaration of Helsinki and
was conducted according to the requirements of the Interna-
tional Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human Use
Guideline for Good Clinical Practice (http://www.ich.org/LOB/
media/MEDIA482.pdf).
Eligible participants were randomly allocated in a
2:2:1:1 ratio to 1 of 4 treatment regimens for 2 years, as
follows: 2 mg of ibandronate administered IV every 2 months
plus daily oral placebo (every-2-months group), 3 mg of
ibandronate administered IV every 3 months plus daily oral
placebo (every-3-months group), 2.5 mg of oral ibandronate
daily plus placebo administered IV every 2 months, or 2.5 mg
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of oral ibandronate daily plus placebo administered IV every 3
months (oral-treatment groups). The cumulative annual dose
of ibandronate (12 mg) was the same for both of the investi-
gational IV regimens. Treatment allocation was performed via
a centralized call-in system (Interactive Voice Response Sys-
tem; ClinPhone Ltd, Nottingham, UK); allocation to treatment
included stratification of patients by center and baseline
lumbar spine BMD reading, to ensure similar distribution
across the treatment groups.
Participants were instructed to take their oral medica-
tion after an overnight fast (6 hours) with 240 ml (8 oz) of
plain water and to maintain an upright posture and fasting
state for at least 60 minutes after dosing. Each IV injection was
given over 15–30 seconds. All patients received supplementary
oral calcium (500 mg/day) and vitamin D (400 IU/day), both of
which were taken in the evening. During the study period,
patients were not allowed to take any other bisphosphonate or
any drug affecting bone metabolism.
Assessments. Primary efficacy parameter. The primary
efficacy parameter was the mean (%) change from baseline at
1 year in the BMD of at least 2 vertebrae in the lumbar spine
(L2–L4) that were not fractured or so affected by degenerative
changes that accurate measurement would be jeopardized.
BMD was measured by dual x-ray absorptiometry (DXA)
scanning (Hologic [Bedford, MA] or GE Lunar [Madison, WI]
instruments), and scans were read at a central reading center
(Synarc, Portland, OR). Scanners were cross calibrated by
circulating cross-calibration phantoms (overall, 23% of scan-
ners required adjustments ranging from 1% to 5%). The
longitudinal precision or stability of each DXA scanner was
monitored, and calibration was performed by establishing a
longitudinal instrument quality control correction factor for
each study center. Coefficients of variation were below longi-
tudinal quality control reference values (0.5% for Hologic and
0.6% for GE Lunar) for all but 5 scanners (longitudinal
correction of BMD measurements was required in 2 cases).
For 8 scanners, patient BMD results were adjusted to remove
the effect of a small but significant linear drift in calibration.
Secondary efficacy parameters. The mean (%) change
from baseline in BMD of the proximal femur (total hip,
femoral neck, and hip trochanter) after 1 year was predefined
as a secondary efficacy parameter, as were BMD responder
rates, defined as the proportion (%) of participants whose
lumbar spine and/or total hip BMD measurements were
greater than or equal to the baseline measurements at 1 year.
The other efficacy parameter analyzed was the median
(%) change from baseline in serum levels of C-telopeptide of
type I collagen (CTX), a biochemical marker of bone resorp-
tion, at 2, 4, 6, and 12 months for patients assigned to the
every-2-months dosing schedule and at 3, 6, and 12 months for
those assigned to the every-3-months schedule. Blood samples
for the assessment of serum CTX were collected just before
the scheduled IV or oral dose, after an overnight fast (6
hours), between 8:00 AM and 10:00 AM. Serum CTX levels
measured in the 2 groups receiving IV medication therefore
represent the residual magnitude of reduction at the end of the
2-month or 3-month dosing interval. Serum CTX assays (the
Elecsys -CrossLaps/Serum assay and the Elecsys 2010 system;
Roche Diagnostics, Basel, Switzerland) were performed at a
central site (Synarc, Lyon, France).
Tolerability and safety assessments. Adverse events were
continuously monitored, classified by body system and pre-
ferred term (using MedDRA version 7.0). Adverse events were
considered to be treatment-related if they were reported as
being remotely, possibly, or probably related to the study
medication.
Physical examinations were performed at the baseline
and 12-month visits. Laboratory safety parameters (e.g., he-
matology and clinical chemistry) were also assessed. Blood
samples for laboratory tests were obtained at the screening
visit and at 3, 4, 6, 8, 9, and 12 months, just before the
scheduled IV dose (active or placebo).
Serum creatinine concentrations were measured at the
time of screening, then again at 4, 8, and 12 months in
the every-2-months arm and at 3, 6, 9, and 12 months in the
every-3-months arm, immediately before the scheduled IV
dose (active drug or placebo). Clinically relevant changes in
the serum creatinine level were defined as either an increase
from baseline of 0.5 mg/dl (if the baseline creatinine level
was within normal limits for age [1.4 mg/dl]) or 1 mg/dl (if
the baseline creatinine level was abnormal [1.4 mg/dl]), or a
2-fold increase from the baseline value at any time point.
Serum creatinine concentrations were also used to estimate
creatinine clearance, using the Cockcroft-Gault equation (17).
Clinical vertebral and nonvertebral fractures were
monitored from adverse event reporting (all fractures were
confirmed radiographically). Flu-like illness, a combination of
the investigator-reported terms influenza-like illness and
acute-phase reaction, was prospectively identified. All events
and events occurring within 3 days of dosing and lasting for7
days, consistent with the typical characteristics of flu-like
illness, were considered.
Electrocardiography (EKG) assessments (12-lead)
were performed before and after administration of the study
drug, at baseline and 6 months, in a subset of patients from the
group receiving medication intravenously every 3 months and
from the groups receiving oral medication, in order to assess
the potential for QT interval prolongation.
Statistical analysis. Sample size calculation. For the
primary efficacy parameter (change [%] from baseline in
lumbar spine BMD), the hypothesis was that the IV and oral
regimens would have the same efficacy (allowing for a maxi-
mum margin of difference between them of 1 percentage
point). Assuming that the standard deviation for the mean
change from baseline in all groups would be 4.5 percentage
points, a sample size of 318 evaluable patients in each group
receiving IV medication (and an aggregate of 318 patients
from the groups receiving medication orally) would be re-
quired to show noninferiority of IV treatment at a significance
level of 2.5% (1-sided parametric t-test) with a statistical power
of 80%. To allow for noncompliant patients and a projected
withdrawal rate of 20%, 1,194 patients in total needed to be
randomly allocated to treatment (398 patients in each IV-
treatment arm and 199 patients in each of the oral-treatment
arms).
Analysis populations. The safety population comprised
all randomized patients who received at least 1 dose of study
medication and had at least 1 followup data point (total
exclusions 13 patients). The intent-to-treat (ITT) population
comprised all randomized patients who received at least 1 dose
of study medication and had at least 1 efficacy data point
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(BMD or serum CTX; total exclusions  37 patients). The
per-protocol (PP) population included all patients in the ITT
population who had no major protocol violations (e.g., no dose
of study medication [n  9], baseline lumbar spine [L2–L4]
BMD T score greater than 2.5 [n  18], poor compliance
with the oral [n  248] or IV [n  165] medication, vitamin D
deficiency [n  1], a concomitant disease that was prohibited
according to the protocol [n  7], use of prohibited treatment
prior to study [n  21], lack of efficacy followup information
[n  28], or lack of reliable BMD data [n  81]; total
exclusions  291 patients).
The PP population was the primary analysis population
for all efficacy end points. The rationale for this was that a PP
population is associated with less variability than is an ITT
population (because the latter includes nonconforming pa-
tients), and protocol violations are more likely to reduce the
treatment effect. For these reasons, analysis of the PP popu-
lation is considered the more conservative and statistically
correct approach for demonstrating noninferiority (18). All
analyses performed on the PP population were to be confirmed
by ITT analysis.
Noninferiority analysis of the primary efficacy variable.
Noninferiority analysis is an established method for demon-
strating the therapeutic equivalence of an investigational drug
and a reference drug (18). In DIVA, this method was used to
compare the change from baseline in lumbar spine BMD
(primary end point) in the 2 groups receiving IV medication
with that in the 2 groups receiving medication orally. Because
the efficacy of oral ibandronate (plus IV placebo every 2
months or every 3 months) was not expected to be influenced
by the treatment schedule, it was planned that all efficacy data
from the 2 oral-treatment groups would be pooled, provided
there were no clinically meaningful differences between base-
line data (clinical and demographic) and the efficacy para-
meters (BMD and serum CTX) at common time points.
In 3 previous studies comparing the effect of oral
ibandronate (2.5 mg) and placebo on the percent change from
baseline in lumbar spine BMD after 1 year (1,19,20), the
smallest difference between the groups was 3.3%. For the
noninferiority analysis in the DIVA study, the allowable
margin of difference between the groups receiving IV medica-
tion and the group (or groups) receiving medication orally was
set at 30% of this difference (1 percentage point). Thus,
noninferiority of the IV regimens could be concluded if the
lower limit of the 2-sided 95% confidence interval (95% CI)
(equivalent to a 1-sided 97.5% CI) for the difference between
both IV regimens and the oral regimen in the mean change in
BMD from baseline was at least –1%. The 2 IV-treatment
groups were compared sequentially (the every-2-months group
first). Only if noninferiority of the IV-treatment groups was
demonstrated could the superiority of the IV regimens to the
oral regimen be tested using an analysis of variance (ANOVA)
model controlling for geographic location and baseline BMD
effects (lumbar spine [L2–L4] BMD T score at least 3 or less
than 3 and at least 3.5 or less than 3.5).
Analysis of other end points. The BMD responder rates
in each treatment group were compared using a chi-square
test, and the absolute and relative changes from baseline in
serum CTX levels were summarized. All adverse events and
abnormal laboratory test results reported during the first year
of the study were included in the safety analysis. The number
and proportion (%) of patients in each group who reported
adverse events were tabulated for comparison. Because report-
ing of adverse events and laboratory safety parameters was not
expected to be influenced by the treatment schedule, most
tolerability and safety data from the 2 groups receiving oral
ibandronate were pooled for analysis (except data on compli-
ance and extent of exposure).
RESULTS
Patient disposition and baseline characteristics.
Patient disposition is summarized in Figure 1. Of 1,804
women screened, 1,395 were randomly allocated to
receive treatment. The sizes of the 3 sample populations
were as follows: for ITT, n  1,358; for PP, n  1,104;
for safety, n  1,382. Because predefined comparisons
of the 2 oral-treatment groups revealed no significant
differences between them (data not shown), they were
pooled for all efficacy analyses. A subset of 244 patients
underwent EKG assessments (157 patients in the every-
3-months group and 87 patients in the oral-treatment
group).
In the PP population, the group sizes were 355,
368, and 381 for the every-2-months group, the every-3-
months group, and the oral-treatment group, respec-
tively. Across all groups, 197 patients withdrew, most
commonly because of adverse events. The demographic
and clinical characteristics of patients at baseline were
well matched across the 3 treatment groups (Table 1).
Figure 1. Patient disposition. “Refused treatment” includes patients
who did not cooperate or withdrew consent. “Other” includes insuffi-
cient therapeutic response, early improvement, violation of selection
criteria at entry, and other protocol violation. q2mo every 2 months;
q3mo  every 3 months.
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Efficacy analysis. Lumbar spine BMD. At 1 year,
similar increases from baseline in lumbar spine BMD
were observed in the group receiving IV medication
every 2 months (mean 5.1%, 95% CI 4.7, 5.5; n  353)
and the group receiving IV medication every 3 months
(mean 4.8%, 95% CI 4.5, 5.2; n  365). These increases
were greater than that in the oral-treatment group
(mean 3.8%, 95% CI 3.4, 4.2; n  377) (Figure 2).
The mean treatment differences (IV minus oral)
for change in lumbar spine BMD from baseline were
1.31% (95% CI 0.76, 1.86) for the every-2-months group
and 1.03% (95% CI 0.49, 1.58) for the every-3-months
group. For both comparisons, the lower 95% confidence
limit was above the prespecified margin for noninferior-
ity of –1%, demonstrating that both IV regimens were
noninferior to the daily regimen (Figure 3). Subsequent
analysis using ANOVA demonstrated that both IV
regimens were statistically superior to the oral regimen
(P  0.001 for both comparisons). The corresponding
analyses performed on the ITT population supported
the findings in the PP population (mean treatment
difference 1.22% [95% CI 0.69, 1.75] for the every-2-
months group and 1.05% (95% CI 0.53, 1.57) for the
every-3-months group; P  0.001 versus oral treatment
for both comparisons).
Proximal femur BMD. After 1 year, the increases
from baseline in BMD of the proximal femur were
similar in the group receiving IV ibandronate every 2
months and the group receiving IV ibandronate every 3
months (2.6% and 2.4%, respectively, for total hip; 2.0%
Figure 2. Mean change from baseline in lumbar spine and proximal
femur bone mineral density after 1 year in the per-protocol population.
q2mo  every 2 months; q3mo  every 3 months. Bars show the 95%
confidence interval.   P  0.05 versus 2.5 mg daily ibandronate.
Figure 3. Noninferiority analysis of mean change (%) from baseline
in lumbar spine (L2–L4) bone mineral density (BMD) after 1 year in
the per-protocol population. Squares and horizontal lines show the
mean difference (and 95% confidence interval) between each group
receiving medication intravenously (IV) and the group receiving
medication orally (expressed as IV minus oral). q3mo  every 3
months; q2mo  every 2 months.
Table 1. Characteristics of all patients in the per-protocol population at baseline*
Characteristic
IV ibandronate,
2 mg every 2 months
(n  355)
IV ibandronate,





Age, years 66.6 65.6 65.5
Weight, kg 64.08 63.92 63.41
Height, cm 158.1 158.1 158.4
Body mass index, kg/m2 25.648 25.623 25.276
Time since menopause, years 19.3 18.2 18.0
Lumbar spine (L2–L4) BMD, gm/cm2 0.747 0.739 0.746
Lumbar spine (L2–L4) BMD, T score 3.3 3.3 3.3
Total hip BMD, gm/cm2 0.744 0.733 0.736
Total hip BMD, T score† 1.909 1.989 1.978
Prevalent fracture, % 41.8 43.2 43.7
Serum CTX, median ng/ml 0.50 0.49 0.51
Serum 25(OH)D, ng/ml 25.22 24.33 24.58
* Except where indicated otherwise, values are the mean. IV  intravenous; BMD  bone mineral density; CTX
 C-telopeptide of type I collagen; 25(OH)D  25-hydroxyvitamin D.
† NHANES III adjusted.
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and 2.3%, respectively, for femoral neck; and 4.1% and
3.8%, respectively, for trochanter) (Figure 2). These in-
creases were significantly greater than those in the
oral-treatment group (1.8%, 1.6%, and 3.0%, respectively;
P  0.05 for all comparisons except the every-2-months
IV regimen versus the oral-treatment regimen at the
femoral neck). Again, corresponding analyses in the
ITT population supported the findings in the PP
population.
Analysis of responder rates for lumbar spine and
total hip BMD. The proportion of patients in the 2
groups receiving IV medication whose lumbar spine
BMD at 1 year was equal to or greater than the baseline
value was significantly larger than that in the oral-
treatment group; responder rates were 92.6% in the
every-2-months group, 92.1% in the every-3-months
group, and 84.9% in the oral-treatment group (P  0.01
for both comparisons). In addition, significantly more
patients in the every-2-months group (86.4%) and the
every-3-months group (82.3%) achieved a total hip
BMD value equal to or greater than the baseline value
than did patients in the oral-treatment group (75.1%;
P  0.01 for both comparisons). The proportion of
patients for whom values for both lumbar spine and total
hip BMD were equal to or greater than baseline values
was also significantly greater in the groups receiving IV
treatment (80.9% and 76.2% in the every-2-months and
every-3-months groups, respectively) than in the oral-
treatment group (67.2%; P  0.01 for both compari-
sons). Compared with the oral-treatment arm, larger
proportions of patients in the IV-treatment arms re-
sponded to treatment with substantial (greater than the
least significant change) increases in lumbar spine BMD
of 6% or total hip BMD of 3% (39.4%, 37.8%, and
26.3% for the lumbar spine and 41.9%, 37.8%, and
33.2% for the total hip in the every-2-months, every-3-
months, and oral-treatment arms, respectively).
Serum CTX. Pronounced decreases from baseline
in serum CTX levels were observed in all treatment
groups at the first sampling point (either 2 or 3 months
after the start of treatment), and levels decreased fur-
ther over the remainder of the study period (Table 2).
After 1 year, the median reduction from baseline in the
serum CTX level was similar in the 3 treatment groups
(64.6% [95% CI 67.2, 62.5], 58.6% [95% CI
61.5, 55.4], and 62.6% [95% CI 66.0, 58.9] in
the every-2-months, every-3-months, and oral-treatment
groups, respectively).




2 mg every 2 months
IV ibandronate,
3 mg every 3 months
Oral ibandronate,
2.5 mg daily
Median (95% CI) n Median (95% CI) n Median (95% CI) n
2 47.1 (51.0, 43.8) 348 – – 45.0 (48.7, 40.5) 181
3 – – 43.2 (45.9, 40.8) 356 54.1 (57.8, 48.7) 192
4 61.4 (63.2, 58.4) 349 – – 57.6 (66.7, 50.0) 180
6 65.1 (67.4, 62.5) 346 58.4 (61.5, 55.2) 353 62.5 (65.3, 60.0) 372
12 64.6 (67.2, 62.5) 345 58.6 (61.5, 55.4) 352 62.6 (66.0, 58.9) 368
* CTX  C-telopeptide of type I collagen; IV  intravenous; 95% CI  95% confidence interval.
Table 3. Proportion of patients in each group who reported adverse events (safety population)*
IV ibandronate,
2 mg every 2 months
(n  448)
IV ibandronate,





Any AE 365 (81.5) 357 (76.1) 360 (77.4)
Any treatment-related AE 197 (44.0) 183 (39.0) 155 (33.3)
Any treatment-related AE
that led to withdrawal
24 (5.4) 31 (6.6) 21 (4.5)
Any SAE 40 (8.9) 35 (7.5) 37 (8.0)
Any treatment-related SAE 4 (0.9) 2 (0.4) 1 (0.2)
Any treatment-related SAE
that led to withdrawal
2 (0.4) 0 (0) 0 (0)
Deaths 1 (0.2) 2 (0.4) 1 (0.2)
* Values are the number (%). Any treatment-related adverse event (AE) or any treatment-related serious
AE (SAE) is an event considered by the investigator to be either remotely, possibly, or probably related
to the study medication. IV  intravenous.
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Safety assessments. Tolerability (adverse events).
After 1 year, the incidence of (proportion of patients
reporting) all adverse events (76–81%), treatment-
related adverse events (33–44%), and treatment-related
adverse events that led to withdrawal (4.5–6.6%) was
similar for the 3 treatment groups (Table 3). The most
frequently reported treatment-related adverse events
involved the GI and musculoskeletal systems, consisting
primarily of dyspepsia (3.4–4.1%), upper abdominal
pain (3.0–3.6%), arthralgia (2.4–3.6%), and flu-like ill-
ness (0.9–4.1%). No cases of avascular necrosis of the
jaw were reported.
Of 112 patients who reported serious adverse
events, 7 reported serious adverse events that were
considered to be at least remotely related to the study
medication, and the incidence of serious adverse events
was similar in the 3 groups (Table 3). Four deaths
occurred, none of which was considered to be related to
the study medication.
Renal tolerability and safety. The incidence of
renal adverse events was low and similar across the
treatment groups (2%, 3%, and 2% in the oral-
treatment, every-2-months, and every-3-months groups,
respectively). No cases of acute renal failure were re-
ported. Serum creatinine levels were similar in all 3
treatment groups at each time point. There was no
change in the mean serum creatinine level from baseline
to month 12 in any treatment group. No patient experi-
enced a continuous increase in the serum creatinine
concentration during the observation period. Six pa-
tients (4 in the every-2-months group and 2 in the
every-3-months group) had a clinically relevant change
in the serum creatinine level at any 1 time point during
the observation period. All of these patients had a
normal baseline serum creatinine level (1.4 mg/dl) and
a temporary elevation of 0.5 mg/dl at a single time
point. For 1 patient, this represented a 2-fold increase
from baseline. Temporary exacerbations of underlying
disorders known to compromise kidney function ap-
peared to be the cause in most (5 of 6) of these patients,
with none of the observed changes considered to be
treatment-related. Baseline creatinine clearance values,
which were estimated using the Cockcroft-Gault equa-
tion, were 90 ml/minute in 95.0% of patients, and 60
ml/minute in 50.5% of patients. The proportion of
patients with any decline in creatinine clearance at any
time point was similar between the every-2-months
group (14.1%), the every-3-months group (17.3%), and
the oral-treatment group (14.1%).
Clinical fractures. At 1 year, no differences in the
number of clinical fractures were observed between the
groups receiving IV treatment and the oral-treatment
group. In total, 43 patients (3.1%) experienced clinical
fractures (radiographically confirmed), including non-
vertebral fractures: 13 fractures each occurred in the
every-2-months group and the every-3-months group,
and 17 fractures occurred in the oral-treatment group.
Flu-like illness. Although the overall incidence of
flu-like illness was low, the incidence was higher in the
groups receiving IV treatment than in the oral-treatment
group (5.1% and 4.9% in the every-2-months and every-
3-months groups, respectively, versus 1.1% in the oral-
treatment group). When the typical onset (within 3 days
of dosing) and duration (7 days) of flu-like illness were
considered, the incidence of flu-like illness in these 3
groups was 3.8%, 3.6%, and 0.6%, respectively. The
specific diagnosis of myalgia was reported for 14 patients
(3.1%), 6 patients (1.3%), and 1 patient (0.2%) in the
every-2-months, every-3-months, and oral-treatment
groups, respectively. In these 3 groups, arthralgia was
reported for 5 patients (1.1%), 6 patients (1.3%), and 1
patient (0.2%), respectively. Most events occurred at the
time of initial administration only (80% of affected
patients reported no repeat symptoms), were generally
mild to moderate in intensity, were transient in nature,
and resolved without any treatment. Withdrawal from
the trial due to these symptoms was rare (0.4% of
patients in the oral-treatment group, 1% of those in the
every-2-months group, and 2.6% of patients in the
every-3-months group).
Cardiac safety. EKG examinations in a subset of
244 patients demonstrated that ibandronate treatment
had no measurable effect on heart rate, atrioventricular
conduction, cardiac depolarization, the QT interval, or
the QT interval corrected for heart rate. In addition,
EKG examination identified no differences between the
oral and IV regimens. In all treatment groups, cardiac
adverse events were infrequent: 5% (n  24) in the
every-2-months group, 3% (n  15) in the every-3-
months group, and 3% (n  12) in the oral-treatment
group.
DISCUSSION
The DIVA study aimed to demonstrate the non-
inferiority of every-2-months and every-3-months regi-
mens of IV ibandronate compared with an approved
regimen of daily oral ibandronate that has previously
shown significant and substantial antifracture efficacy in
postmenopausal women with osteoporosis (3-year verte-
bral fracture risk reduction, 52%) (1). The results pre-
sented in this report show the effects after 1 year of
treatment. Both of the IV regimens produced a similar
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increase from baseline in lumbar spine BMD (5.1% and
4.8%) that was greater than that provided by the regi-
men of daily oral ibandronate (3.8%). Prespecified
statistical analyses demonstrated the noninferiority of
both IV-treatment regimens compared with the oral-
treatment regimen. The superiority of both IV-
treatment regimens compared with the oral-treatment
regimen was also prospectively proven. Results for sec-
ondary efficacy parameters consistently supported the
results for the primary study end point. Increases from
baseline in total hip BMD were similar in the 2 groups
receiving IV medication (2.6% and 2.4%), as were the
proportions of patients responding to treatment with
BMD increases: similar and substantial proportions of
patients in the 2 IV-treatment groups achieved lumbar
spine and/or total hip BMD readings that were equal to
or greater than baseline values.
The degree of reduction in the level of the bone
resorption marker serum CTX was similar in all 3 groups
in our study, after both 6 and 12 months. This finding is
noteworthy, because the magnitude of bone resorption
marker reduction observed in the 2 groups receiving IV
medication compares favorably with that noted at 3
years in the BONE study (1). In that study, 3 years of
treatment with 2.5 mg of oral ibandronate daily pro-
duced a 52% reduction in the risk of vertebral fractures
and a 6.5% increase in lumbar spine BMD (1). These
effects were accompanied by a reduction in the level of
bone resorption markers (as assessed by the urinary
concentration of CTX corrected for creatinine) of 65.3%
at 3 years (2). In previous studies of IV ibandronate that
used lower doses (0.5 mg and 1 mg every 3 months) than
those used in the DIVA study, the reduction in bone
turnover was only modest (7.3% and 10.8%, respec-
tively, versus placebo), leading to suboptimal increases
in lumbar spine BMD of 3.9% and 4.9%, respectively,
after 3 years and an insignificant reduction in the risk of
vertebral fracture (21). However, the dose dependency
of these effects was demonstrated by the Intermittent
Regimen Intravenous Ibandronate Study, in which a
larger IV dose given with the same dose-free interval (2
mg every 3 months) for just 1 year produced significantly
greater lumbar spine (L1–L4) BMD increases and de-
creases in the level of urinary CTX/creatinine than those
observed with the regimen in which 1 mg was adminis-
tered every 3 months (15).
At the currently studied doses, IV ibandronate
injections were well tolerated, with safety and tolerabil-
ity profiles similar to those for daily oral ibandronate,
with no renal tolerability concerns as have been ob-
served with other IV bisphosphonates (22–25). These
results are consistent with those previously reported for
IV ibandronate injections (14,15,21,26,27). The inci-
dence of flu-like illness was, as expected, higher in the
groups receiving IV medication than in the group receiv-
ing oral medication. Nevertheless, the absolute inci-
dence of this event, as well as the incidence of myalgia
and arthralgia, was low (1.1–5.1% in the IV-treatment
groups and 0.2–0.6% in the oral-treatment group).
Symptoms mostly occurred at the time of the first IV
injection (80% of affected patients reported no repeat
symptoms) and were generally mild to moderate in
intensity and transient in nature.
The findings of the DIVA study indicate that IV
ibandronate injections administered every 2 months or
every 3 months are at least as effective and similarly well
tolerated as an established regimen of daily oral iban-
dronate, in postmenopausal women with osteoporosis.
Intravenous administration of ibandronate is likely to be
advantageous for patients who cannot tolerate oral
bisphosphonates or have difficulty complying with oral
treatment.
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